MedTrace Logo

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00030602 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-11-05

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent prostate cancer.

Conditions

Interventions

BIOLOGICAL

PSA prostate cancer vaccine

BIOLOGICAL

incomplete Freund's adjuvant

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Nancy A. Dawson, MD · University of Maryland Greenebaum Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2001-12-31
Completion
2001-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030602 on ClinicalTrials.gov